Global Market Direct’s pharmaceuticals report, “Biotec Pharmacon ASA - Product Pipeline Review - 2013” provides data on the Biotec Pharmacon ASA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biotec Pharmacon ASA’s corporate website, SEC filings, investor presentations and featured press releases, both from Biotec Pharmacon ASA and industry-specific third party sources, put together by Global Markets Direct’s team.
- Biotec Pharmacon ASA - Brief Biotec Pharmacon ASA overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Biotec Pharmacon ASA human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Biotec Pharmacon ASA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Biotec Pharmacon ASA’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Biotec Pharmacon ASA’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Biotec Pharmacon ASA in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Biotec Pharmacon ASA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Biotec Pharmacon ASA. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Biotec Pharmacon ASA and identify potential opportunities in those areas.